[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621848":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":24,"responsibleParty":44,"collaborators":18,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":18,"overallStatus":27,"whyStopped":18,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TNK group","EXPERIMENTAL","Tenecteplase is administered intravenously at a dose of 16 mg, with a maximum dose of 0.25 mg\u002Fkg.",[13],"Drug: Tenecteplase",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","No tenecteplase",null,[20],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":18},"DRUG","Tenecteplase",[9],[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Yu Cui","RECRUITING","Shenyang","None Selected","110840","China","CN",{"type":34,"coordinates":35},"Point",[36,37],123.43278,41.79222,{"lat":37,"lon":36},[40],{"name":26,"role":41,"phone":42,"phoneExt":18,"email":43},"CONTACT","02428897499","cuiyu.spu@hotmail.com",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Hui-Sheng Chen","Director","100621848","phase-2-repeated-intravenous-thrombolysis-for-ischemic-stroke-within-30-hours-of-onset-with-tenecteplase-ritis-tnk-100621848",false,"NCT07375953","Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK)","Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK): a Prospective, Randomized, Open Label, Blinded Assessment of Outcome, and Multi-center Study","RITIS-TNK","Inclusion Criteria:\n\n* Age ≥ 18 year;\n* Acute ischemic stroke within 3 hours of onset, having received standard intravenous thrombolysis;\n* Measurable neurological deficit before the first intravenous thrombolysis, with NIHSS ≥ 4;\n* No significant clinical improvement (reduction in NIHSS ≤ 2) or neurological deterioration after initial improvement at 1 hour after the first thrombolysis, with intracranial hemorrhage ruled out by neuroimaging;\n* The second intravenous thrombolysis can be administered within 4.5 hours of onset;\n* First stroke onset or past stroke without obvious neurological deficit (mRS≤1);\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Planed for endovascular treatment;\n* Significant cerebral white matter hyperintensities (Fazekas score 3)；\n* Any coagulation abnormality before the first thrombolysis, including INR \\> 1.5；\n* Pregnancy；\n* Allergy to the investigational drug(s)；\n* Receipt of dual antiplatelet therapy within 24 hours prior to thrombolysis;\n* Comorbidity with other serious diseases;\n* Participating in other clinical trials within 3 months;\n* Patients not suitable for the study considered by researcher.","ALL","18 Years","80 Years",{"count":60,"type":61},120,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","Despite being the standard pharmacological reperfusion therapy for acute ischemic stroke, intravenous thrombolysis is limited by suboptimal recanalization rates. Tenecteplase (TNK), a newer thrombolytic agent, offers practical advantages over alteplase, including single bolus administration. However, a significant proportion of patients fail to achieve early clinical improvement after standard thrombolysis, likely due to persistent vessel occlusion.\n\nThis study proposes to investigate a rescue strategy for patients who do not show significant neurological improvement within one hour after receiving standard intravenous tenecteplase within 3 hours of stroke onset. The primary objective is to evaluate the safety and feasibility of administering a second dose of tenecteplase in this scenario. The study will also explore the potential efficacy of this approach in improving recanalization and functional outcomes.",[67],"Ischemic Stroke","2026-03-31",{"date":70,"type":71},"2026-04-01","ACTUAL",{"date":73,"type":71},"2026-03-25",{"date":75,"type":61},"2027-12-30",{"name":5,"class":6},1]